NCT00745511View on ClinicalTrials.gov

Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Macular Degeneration
Interventions
DRUG

ORA102 and Avastin

treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102

DRUG

Avastin

treatment with intravitreal injections of Avastin 1.25mg (0.05ml)

Trial Locations (5)

Unknown

RECRUITING

Barzilai Medical Center, Ashkelon

RECRUITING

Carmel Medical Center, Haifa

RECRUITING

Hadassah Medical center Israel, Jerusalem

RECRUITING

Ziv Medical Center, Safed

RECRUITING

Tel-Aviv Sourasky Medical Center, Tel Aviv

Sponsors

Lead Sponsor

Ora Bio Ltd.
All Listed Sponsors
lead

Ora Bio Ltd.

INDUSTRY

NCT00745511 - Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter